Portal de Periódicos da CAPES

Clinical Pharmacology and Pharmacodynamics of Irinotecan

1996; Wiley; Volume: 803; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.1996.tb26385.x

1749-6632

Guy G. Chabot,

Neutropenia and Cancer Infections

Annals of the New York Academy of SciencesVolume 803, Issue 1 p. 164-172 Clinical Pharmacology and Pharmacodynamics of Irinotecan A Reviewa GUY G. CHABOT, GUY G. CHABOT Pharmacology Laboratory (URA 147 CNRS) Institut Gustave-Roussy (PR-2) 39, rue Camille-Desmoulins 94805 Villejuif Cedex, FranceSearch for more papers by this author GUY G. CHABOT, GUY G. CHABOT Pharmacology Laboratory (URA 147 CNRS) Institut Gustave-Roussy (PR-2) 39, rue Camille-Desmoulins 94805 Villejuif Cedex, FranceSearch for more papers by this author First published: December 1996 https://doi.org/10.1111/j.1749-6632.1996.tb26385.xCitations: 10 a The following organizations made these studies possible: the Institut National de la Santé et de la Recherche Médicale (INSERM), the Centre National de la Recherche Scientifique (CNRS), the Laboratoire Bellon, and the Association pour la Recherche sur le Cancer (Villejuif, France). AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Wall, M. E., M. C. Wani, C. E. Cook, K. H. Palmer, A. T. McPhail & G. A. Sim. 1966. Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 88: 3888– 3890. 2 Li, L. H., T. J. Fraser, E. J. Olin & B. K. Bhuyan. 1972. Action of camptothecin on mammalian cells in cultures. Cancer Res. 32: 2643– 2650. 3 Drewinko, B., E. J. Freireich & J. A. Gottlieb. 1974. Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res. 34: 747– 750. 4 Gallo, R. C., J. Whang-Peng & R. H. Adamson. 1971. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J. Natl. Cancer Inst. 46: 789– 795. 5 Gottlieb, J. A., A. M. Guarino, J. B. Call, V. T. Oliverio & J. B. Block. 1970. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother. Rep. 54: 461– 470. 6 Gottlieb, J. A. & J. K. Luce. 1972. Treatment of malignant melanoma with camptothecin (NSC 100880). Cancer Chemother. Rep. 56: 103– 105. 7 Moertel, C. G., A. J. Schutt, R. J. Reitmeier & R. G. Hahn. 1972. Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastro-intestinal cancer. Cancer Chemother. Rep. 56: 95– 101. 8 Muggia, F. M., P. J. Creaven, H. H. Hansen & O. S. Selawry. 1972. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): correlation with preclinical studies. Cancer Chemother. Rep. 56: 515– 521. 9 Creaven, P. J., L. M. Allen & F. M. Muggia. 1972. Plasma camptothecin (NSC 100880) levels during a 5-day course of treatment: Relation to dose and toxicity. Cancer Chemother. Rep. 56: 573– 578. 10 Schaeppi, V., R. W. Fleischman & D. A. Cooney. 1974. Toxicity of camptothecin (NSC 100880). Cancer Chemother. Rep. 58: 25– 36. 11 Kunimoto, T., K. Nitta, T. Tanaka, N. Uehara, H. Baba, M. Takeuchi, T. Yokokura, S. Sawada, T. Miyasaka & M. Mutai. 1987. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 47: 5944– 5947. 12 Tsuruo, T., T. Matsuzaki, M. Matsushita, H. Saito & T. Yokokura. 1988. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 21: 71– 74. 13 Bissery, M. C., A. Mathieu-Boue & F. Lavelle. 1991. Preclinical evaluation of CPT-11, a camptothecin derivative. Proc. Am. Assoc. Cancer Res. 32: 402 (abstract). 14 Houghton, P. J., P. J. Cheshire, J. C. Hallman, M. C. Bissery, A. Mathieu-Boue & J. A. Houghton. 1993. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res. 53: 2823– 2829. 15 Vassal, G., J. Morizet, M. C. Bissery, I. Boland, P. Ardouin, A. Mathieu-Boue, & A. Gouyette. 1994. Activity of the camptothecin analog CPT-11 (irinotecan) against medulloblastoma xenographts. Proc. Am. Assoc. Cancer Res. 35: 366 (abstract). 16 Bissery, M. C., P. Vrignaud, F. Lavelle & G. G. Chabot. 1996. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anti-Cancer Drugs. Anti-Cancer Drugs 7: 437– 460. 17 Hsiang, Y. H., R. Hertzberg, S. Hecht & L. F. Liu. 1985. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260: 14873– 14878. 18 Hsiang, Y. H. & L. F. Liu. 1988. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48: 1722– 1726. 19 Hsiang, Y. H., L. F. Liu M. E. Wall, M. C. Wani, A. W. Nicholas, G. Manikumar, S. Kirschenbaum, R. Silber & M. Potmesil. 1989. DNA topoisomerase I mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res. 49: 4835– 4839. 20 Kessel, D., H. B. Bosmann & K. Lohr. 1972. Camptothecin effects on DNA synthesis in murine leukemia cells. Biochem. Biophys. Acta 269: 210– 216. 21 Wang, J. C. 1985. DNA topoisomerases. Annu. Rev. Biochem. 54: 665– 697. 22 Liu, L. F. 1989. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58: 351– 375. 23 Gupta, R. S., R. Gupta, B. Eng, R. B. Lock, W. E. Ross, R. P. Hertzberg, M. J. Caranfa & R. K. Johnson. 1988. Camptothecin-resistant mutants of chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res. 48: 6404– 6410. 24 Kanzawa, F., Y. Sugimoto, K. Minato, K. Kasahara, M. Bungo, K. Nakagawa, Y. Fujiwara, F. Liu & N. Saijo. 1990. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human small cell lung cancer: Characterization and mechanism of resistance. Cancer Res. 50: 5919– 5924. 25 Sugimoto, Y., S. Tsukahara, T. Oh-Hara, T. Isoe & T. Tsuruo. 1990. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 50: 6925– 6930. 26 Tamura, H., C. Kohchi & R. Yamada. 1991. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res. 51: 1129– 1136. 27 Chen, A. Y., C. Yu, M. Potmesil, M. E. Wall, M. C. Wani & L. F. Liu. 1991. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res. 51: 6039– 6044. 28 Kawato, Y., M. Aonuma, Y. Hirota, H. Kuga & K. Sato. 1991. Intracellular roles of SN-38, a metabolite of the camptothecin derivative, CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51: 4187– 4191. 29 Ohno, R., K. Okada, T. Masaoka, A. Kuramoto, T. Arima, Y. Yoshida, H. Ariyoshi, M. Ichimaru, Y. Sakai, M. Oguro, Y. Ito, Y. Morishima, S. Yokomaku & K. Ota. 1990. An early phase II study of CPT-11: A new derivative of camptothecin for the treatment of leukemia and lymphoma. J. Clin. Oncol. 8: 1907– 1912. 30 Taguchi, T., A. Wakui & K. Hasegawa. 1990. Phase I clinical study of CPT-11. Research Group of CPT-11. Jpn. J. Cancer Chemother., 17: 115– 120. 31 Negoro, S., M. Fukuoka, N. Masuda, M. Takada, Y. Kusunoki, K. Matsui, N. Takifuji, S. Kudoh, H. Niitani & T. Taguchi. 1991. Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advance non-small cell lung cancer. J. Natl. Cancer Inst. 83: 1164– 1168. 32 Ohe, Y., Y. Sasaki, T. Shinkai, K. Eguchi, T. Tamura, A. Kojima, H. Kunikane, H. Okamoto, A. Karato, H. Ohmatsu, F. Kanzawa & N. Saijo. 1992. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J. Natl. Cancer Inst. 84: 972– 974. 33 Rothenberg, M. L., J. G. Kuhn, H. A. Burris III, J. Nelson, J. R. Eckardt, M. Tristan-Morales, S. G. Hilsenbeck, G. R. Weiss, L. S. Smith, G. I. Rodriguez, M. K. Rock & D. D. Von Hoff 1993. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11: 2194– 2204. 34 Rowinsky, E. K., L. B. Grochow, D. S. Ettinger, S. E. Sartorius, B. G. Lubejko, T. L. Chen, M. K. Rock & R. C. Donehower. 1994. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino-]carbonyl-oxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res. 54: 427– 436. 35 Fukuoka, M., H. Nitani, A. Suzuki, M. Motomiya, K. Hasegawa, Y. Nishiwaki, T. Kuriyama, Y. Ariyoshi, S. Negoro, N. Masuda, S. Nakajima & T. Taguchi. 1992. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J. Clin. Oncol. 10: 16– 20. 36 Burris, H. A., M. L. Rothenberg, J. G. Kuhn & D. D. Von Hoff 1992. Clinical trials with the topoisomerase I inhibitors. Semin. Oncol. 19: 663– 669. 37 Slichenmyer, W. J., E. K. Rowinsky, R. C. Donehower & S. H. Kaufmann. 1993. The current status of camptothecin analogues as antitumor agents (review). J. Natl. Cancer Inst. 85: 271– 291. 38 Masuda, N., M. Fukuoka, Y. Kusunoki, K. Matsui, Takifuji, S., Kudoh, S. Negoro, M. Nishioka, K. Nakagawa & M. Takada. 1992. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol., 10: 1225– 1229. 39 Ogawa, M. & T. Taguchi. 1992. Clinical studies with CPT-11: The Japanese experience. 1992. Ann. Oncol. 3 (Suppl. 1): 118 (abstract 239). 40 Catimel, G., G. G. Chabot, J. P. Guastalla, A. Dumortier, C. Cote, C. Engel, A. Gouyette, A. Mathieu-Boue, M. Mahjoubi & M. Clavel. 1995. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann. Oncol. 6: 133– 140. 41 DeForni, M., R. Bugat, G. G. Chabot, S. Culine, J. M. Extra, A. Gouyette, I. Madelaine, M. E. Marty & A. Mathieu-Boue. 1994. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan administered on a weekly schedule in cancer patients. Cancer Res. 54: 4347– 4354. 42 Abigerges, D., G. G. Chabot, J. P. Armand, P. Herait, A. Gouyette & D. Gandia. 1995. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol. 13: 210– 221. 43 Barilero, I., D. Gandia, J. P. Armand, A. Mathieu-Boue, M. Re, A. Gouyette & G. G. Chabot. 1992. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography–Application to plasma pharmacokinetic studies in cancer patients. J. Chromatogr. (Biomed. Appl.) 575: 275– 280. 44 Chabot, G. G., D. Abigerges, G. Catimel, S. Culine, M. DeForni, J. M. Extra, M. Mahjoubi, P. Herait, J. P. Armand, R. Bugat, M. Clavel & M. E. Marty. 1995. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann. Oncol 6: 141– 151. 45 Rowinsky, E. K., L. B. Grochow, C. B. Hendricks, D. S. Ettinger, A. A. Forastiere, L. A. Hurowitz, W. P. McGuire, S. E. Sartorius, B. G. Lubejko, S. H. Kaufmann & R. C. Donehower. 1992. Phase I and pharmacology study of topo-tecan: A novel topoisomerase I inhibitor. J. Clin. Oncol. 10: 647– 656. 46 Kaneda, N., H. Nagata, T. Furuta & T. Yokokura. 1990. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 50: 1715– 1720. 47 Kaneda, N. & T. Yokokura. 1990. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res. 50: 1721– 1725. 48 Masuda, N., M. Fukuoka, S. Kudoh, K. Matsui, Y. Kusunoki, M. Takada, K. Nagakawa, T. Hirashima, H. Tsukada, T. Yana, A. Yoshikawa, A. Kubo, E. Matsuura, T., Mitta, N. Takifuji, K. Terakawa & S. Negoro. 1994. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J. Clin. Oncol. 12: 1833– 1841. 49 Tsuji, T., N. Kaneda, K. Kado, T. Yokokura, T. Yoshimoto & D. Sturu. 1991. CPT-11 converting enzyme from rat serum: Purification and some properties. J. Pharmacobiodyn. 14: 341– 349. 50 Chabot, G. G. 1994. Factors involved in clinical pharmacology variability in oncology (review). Anticancer Res. 14: 2269– 2272. 51 Gupta, E., T. M. Lestingi, R. Mick, J. Ramirez, E. E. Vokes & M. J. Ratain. 1994. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res. 54: 3723– 3725. 52 Gandia, D., D. Abigerges, J. P. Armand, G. G. Chabot, L. Da Costa & M. De Forni 1993. CPT-11-Induced cholinergic effects in cancer patients. J. Clin. Oncol. 11: 196– 197 (letter). 53 Chabot, G. G. 1995. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38. Cancer Chemother. Pharmacol. 36: 463– 472. Citing Literature Volume803, Issue1The Camptothecins: From Discovery to the PatientDecember 1996Pages 164-172 ReferencesRelatedInformation